We report a case of natural killer cell large granular lymphocytic (NK-LGL) leukaemia successfully treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). The peripheral blood (PB) revealed an abnormal expansion of LGL that were CD3 
tained. [6] [7] [8] NK-LGL leukaemia is highly resistant to chemotherapy. 5 To our knowledge, successful treatment of NK-LGL leukaemia has been achieved only with allogeneic bone marrow transplantation (allo-BMT). 9 We report a case of Epstein-Barr virus (EBV)-associated NK-LGL leukaemia successfully treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT).
Case report
An 18-year-old Japanese man presented with high fever, anorexia, sore throat, and abdominal pain that had lasted for 10 weeks. Physical examination revealed a temperature of 39°C, erosive swelling of the tonsils, tender enlargement of the liver, and a palpable spleen. There was no peripheral lymphadenopathy. A blood count showed a hemoglobin concentration of 11.7 g/dl, a platelet count of 148 ϫ 10 9 /l, and a white blood cell count (WBC) of 25. In situ hybridization of the patient's peripheral blood mononuclear cells (PBMC) using an anti-sense probe for the highly transcribed EBV-encoded small nuclear RNA (EBER)-1 sequence revealed the presence of EBV-RNA in the LGL (Figure 1 ) as well as in infiltrating lymphocytes seen in both sections of the resected tonsils and the colon biopsy. The NK activity of the PBMC from the patient against K562 cells was considerably higher than that seen in normal individuals (45% vs 20% at an effector:target ratio of 10:1). When the PBMC from the patient were examined for their antibody-dependent cellular cytotoxicity (ADCC) using P815 coated with rabbit IgG as a target, they showed similar cytotoxicities to those from normal individuals. Southern blot analysis showed the genes of both T cell receptor (TCR) ␤ and ␥ chains, 10 and the immunoglobulin heavy chain 11 to be in the germline configuration. Southern blotting with an EBVterminal repetitive (EBTR) sequence probe 6 demonstrated clonal proliferation of EBV + cells (Figure 2 ). Based on these findings, NK-LGL leukaemia associated with EBV was diagnosed.
Oral administration of 100 mg of cyclophosphamide (CY) for 3 weeks had no beneficial effect. Further chemotherapy was not undertaken since it appeared to produce toxicities without benefit. Then, the patient was subjected to PBSCT from his HLA-matched EBV-seropositive sister 4 months after the diagnosis. The preparative regimen included fractionated total body irradiation (FTBI; 3.0 Gy ϫ 4) and administration of 120 mg/kg of CY. The donor was treated daily with subcutaneous injections of granulocyte colony-stimulating factor (G-CSF; filgrastim), 6 g/kg, for 5 consecutive days. Peripheral blood stem cells (PBSC) were collected by leukapheresis using the Cobe Spectra Cell Separator (Cobe Laboratories, Lakewood, CO, USA) on the fourth and fifth day of G-CSF administration and a total of 13 ϫ 10 6 CD34 + cells/kg were infused into the patient. Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporine and short-term methotrexate. On the second day of FTBI, the patient's fever subsided and he remained afebrile throughout the post-transplantion period. Trilineage haematopoiesis promptly recovered without the development of GVHD (Figure 3) . On day 27, peripheral blood lymphocytes were predominantly CD3
+ and the proportion of LGL returned to the normal range. Fluorescence in situ hybridization with a probe for the Y chromosome showed no recipient-derived cells in the blood and marrow. Polymerase chain reaction (PCR) analysis of a variable number of tandem repeats LGL, large granular lymphocytes; FTBI, fractionated total body irradiation; CY, cyclophosphamide; allo-PBSCT, allogeneic peripheral blood stem cell transplantation.
locus in the DNA of peripheral blood cells obtained on day 21 after allo-PBSCT amplified only donor-derived alleles.
In situ hybridization showed the PBMC taken on day 21 were EBER-1 negative as well as the colon biopsy on day 28. Southern blotting with an EBTR sequence probe did not detect EBV sequences in the DNA from PBMC obtained 5 months after allo-PBSCT. The patient has been in complete remission without therapy for 10 months since the allo-PBSCT.
Discussion
Although NK-GLPD is thought to be caused by EBV, its aetiology is still uncertain. EBV is frequently detected in NK cells of Oriental patients, 4, 6 but rarely in patients in the United States and Europe. 7, 12 The clinical course of NK-GLPD varies from one patient to another even in those with EBV-associated clonal NK-GLPD. Some patients present with progressive symptoms resembling those of acute leukaemia, and others have an indolent phase followed by acceleration of the disease. 3, 6, 8 It is thus difficult to decide when and how these patients should be treated with cytotoxic agents.
NK-LGL leukaemia is reported to be highly resistant to combination chemotherapy, such as vincristine plus doxorubicin and etoposide plus cytarabine. 5, 9 To our knowledge, there is no report of a patient who was successfully treated with conventional chemotherapy. Yamamoto et al 13 reported that the NK cells of three patients with NK-GLPD all expressed P-glycoprotein, as seen in our patient, and suggested that P-glycoprotein may be responsible for the refractoriness of the leukaemia to chemotherapy. Based on these previous data, we avoided treating our patient with intensive chemotherapy and treated him with low-dose CY therapy instead. However, his high fever persisted and disseminated intravascular coagulation developed in 7 weeks from the initiation of the therapy. Thus, we decided to treat the patient with allogeneic haematopoietic stem cell transplantation. Allo-PBSCT rather than allo-BMT was chosen considering the poor clinical condition of the patient and because of a demonstrated advantage of allo-PBSCT with regard to mortality in the early post-transplant period over allo-BMT. 14 The clinical course of the leukaemia in our patient suggested that allo-PBSCT with a conditioning regimen involving the use of CY and FTBI can eradicate the NK-LGL leukaemic cells even when there is a large leukaemic burden. Allogeneic stem cell transplantation is probably the only treatment for this intractable disease. 9 Allo-PBSCT may be preferable to allo-BMT since a large number of T cells infused with stem cells may produce a potent graftversus-leukaemia effect. 15 Long-term follow-up is required to determine whether stable remission after allo-PBSCT leads to a cure for NK-LGL leukaemia.
